News

In a recent development, Antengene Corporation Limited announced a global clinical collaboration with Merck (NYSE:MRK) to evaluate ATG-022 in combination with KEYTRUDA®, which could enhance Merck's ...
Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...
Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...
Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...
Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing ...
Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ...
Pfizer will pay China’s 3SBio $1.25 billion upfront to gain access to a cancer therapy that could rival Akeso and Summit’s ...
Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...
MSD has reported that the Phase III KEYNOTE-B96 trial of Keytruda plus paclitaxel, with or without bevacizumab, has met its ...
In October, Merck announced that the Phase 3 KEYNOTE-689 trial of Keytruda, as a perioperative treatment for patients newly diagnosed with stage III or IVA, resected, locally advanced head and ...